Ann Dermatol.
2021 Dec;33(6):584-586. 10.5021/ad.2021.33.6.584.
Abrupt Development of Esophageal Candidiasis after Secukinumab Treatment in a Psoriatic Patient
- Affiliations
-
- 1Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea
- KMID: 2522142
- DOI: http://doi.org/10.5021/ad.2021.33.6.584
Abstract
- no abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Recurrent Esophageal Candidiasis Induced by Secukinumab: Discrepancy between Clinical Trials and Real-World Data
- Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis and Moderate-to-Severe Psoriasis Receiving Secukinumab: A Retrospective Study
- Recurrent Esophageal Stricture Caused by Candidiasis in an HIV-Infected Patient
- A case of esophageal candidiasis caused by inhaled corticosteroid
- Progression of Pre-Existing Vitiligo during Secukinumab Treatment for Psoriasis
